Adverse events after hepatitis A B combination vaccine

Vaccine

Volumn 24, Issue 14, 2006, Pages 2685-2691

  Woo, Emily Jane ^a   Miller, Nancy B ^a   Ball, Robert ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse event; Hepatitis A; Hepatitis B; Twinrix

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIPHTHERIA TETANUS TOXOID; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE; YELLOW FEVER VACCINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APPETITE DISORDER; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BILIRUBIN BLOOD LEVEL; BRONCHOSPASM; CEREBROVASCULAR ACCIDENT; CHILD; CHOLELITHIASIS; CLINICAL FEATURE; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DIARRHEA; DIPLOPIA; DISEASE EXACERBATION; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENCEPHALITIS; FEMALE; FEVER; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEADACHE; HEPATITIS A; HEPATITIS B; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INTUSSUSCEPTION; LASSITUDE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MENINGITIS; MENINGOCOCCEMIA; MORTALITY; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOSIS; MYELITIS; NAUSEA; NONHODGKIN LYMPHOMA; PANCREATITIS; PARASITOSIS; PARESTHESIA; POSTVACCINAL ENCEPHALITIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RASH; RHEUMATIC DISEASE; SEIZURE; SYNCOPE; TOXIC EPIDERMAL NECROLYSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VIRUS HEPATITIS; VIRUS INFECTION; VIRUS MENINGITIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; VACCINES, COMBINED;

EID: 33344461520     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.10.049     Document Type: Article

References (27)

1. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(No. RR-13).
2. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12).
3. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51(RR-6):1-78.
4. Twinrix® Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine. Physicians' Desk Reference (PDR). Montvale, NJ: Thomson PDR; 2003. p. 1669-72.
5. V. Prado, S. Riedemann, H. Ibarra, and M. Potin Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in healthy Chilean subjects Int J Infect Dis 6 2 2002 129 133
6. D.L. Murdoch, K. Goa, and D.P. Figgitt Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability Drugs 63 23 2003 2625 2649
7. ®) in adults Vaccine 19 32 2001 4710 4719
8. P. Van Damme, and K. Van Herck A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine Expert Rev Vaccines 3 3 2004 249 267
9. Havrix® - Hepatitis A Vaccine, Inactivated. Physicians' Desk Reference (PDR). Montvale, NJ: Thomson PDR; 2003. p. 1536-38.
10. Engerix-B® Hepatitis B Vaccine (Recombinant). Physicians' Desk Reference (PDR). Montvale, NJ: Thomson PDR; 2003. p. 1505-07.
11. GlaxoSmithKline, Data on file, TWR401.
12. M.T. Niu, M. Salive, C. Krueger, and S.S. Ellenberg Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS) Clin Infect Dis 26 6 1998 1475 1476
13. F.E. Shaw Jr., D.J. Graham, H.A. Guess, J.B. Milstien, J.M. Johnson, and G.C. Schatz Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years Am J Epidemiol 127 2 1988 337 352
14. Immunization Safety Review Committee, Institute of Medicine. Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington, DC: National Academy Press; 2002.
15. Code of Federal Regulations. 21 CFR 600.80. US Government Printing Office, 2001.
16. R.T. Chen, S.C. Rastogi, and J.R. Mullen The Vaccine Adverse Event Reporting System (VAERS) Vaccine 12 6 1994 542 550
17. S.S. Ellenberg, and M.M. Braun Monitoring the safety of vaccines: assessing the risks Drug Saf 25 3 2002 145 152
18. F. Varricchio, J. Iskander, and F. Destefano Understanding vaccine safety information from the Vaccine Adverse Event Reporting System Pediatr Infect Dis J 23 4 2004 287 294
19. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999;48(43):1007.
20. S.J. Evans, P.C. Waller, and S. Davis Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports Pharmacoepidemiol Drug Saf 10 6 2001 483 486
21. R.P. Wise, J. Iskander, R.D. Pratt, S. Campbell, R. Ball, and R.P. Pless Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine JAMA 292 14 2004 1702 1710
22. Guidance for Industry. Postmarketing safety reporting for human drug and biological products including vaccines. Food and Drug Administration, US Department of Health and Human Services, March 2001. www.fda.gov/cder/guidance/ 4177dft.pdf.
23. M. Salas, A. Hofman, and B.H. Stricker Confounding by indication: an example of variation in the use of epidemiologic terminology Am J Epidemiol 149 11 1999 981 983
24. D.Y. Li, and K.B. Schwarz Autoimmune hepatitis Adolesc Med Clin 15 1 2004 131 143
25. S. Vento, T. Garofano, G. Di Perri, L. Dolci, E. Concia, and D. Bassetti Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals Lancet 337 8751 1991 1183 1187
26. T. Laskus, and J. Slusarczyk Autoimmune chronic active hepatitis developing after acute type B hepatitis Dig Dis Sci 34 8 1989 1294 1297
27. Recombivax HB® - Hepatitis B Vaccine (Recombinant). Physicians' Desk Reference (PDR). Montvale, NJ: Thomson PDR; 2003. p. 2083-86.